← FDA DRUG APPROVALS

FDA ANDA · ANDA207400

CAFFEINE CITRATE

Sponsor: MICRO LABS

APPLICATION
ANDA207400
TYPE
ANDA
ORIGINAL APPROVAL
2017-12-14
LATEST ACTION
2020-11-12
ROUTE
INTRAVENOUS, INTRAMUSCULAR
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

CAFFEINE CITRATEPrescription
CAFFEINE CITRATE EQ 30MG BASE/3ML (EQ 10MG BASE/ML) · SOLUTION · INTRAVENOUS

Approval history

2020-11-12Labeling · Supplement 4 · standardAP
2020-11-12Labeling · Supplement 5 · standardAP
2020-11-12Labeling · Supplement 3 · standardAP
2017-12-14UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →